Viewing Study NCT03969550



Ignite Creation Date: 2024-05-06 @ 1:13 PM
Last Modification Date: 2024-10-26 @ 1:11 PM
Study NCT ID: NCT03969550
Status: COMPLETED
Last Update Posted: 2019-05-31
First Post: 2019-05-29

Brief Title: Do CCR5 Antagonists Improve the Overall Survival of Patients With AIDS-related Progressive Multifocal Leucoencephalopathy
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Organization: Fondation Ophtalmologique Adolphe de Rothschild

Study Overview

Official Title: Do CCR5 Antagonists Improve the Overall Survival of Patients With AIDS-related Progressive Multifocal Leucoencephalopathy
Status: COMPLETED
Status Verified Date: 2019-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Progressive multifocal leucoencephalopathy PML is a demyelinating disease caused by John Cunningham virus JCV reactivation Numerous molecules have been overstated because there were inaccurately tested in non-rigorous clinical trial

The objective is to draw lessons from repeatedly false hopes of unconfirmed PML treatments that might contribute to prescribing ineffective drugs on claimed efficacy in case reports or small series and by failing to respect the need for clinical trial evaluation before authorizing their widespread use
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None